ReviewCancer science2017
Epigenetics in normal and malignant hematopoiesis: An overview and update 2017.
Review in Cancer science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 47 citations in OpenAlex.
- Metabolic checkpoints in glioblastomas: targets for new therapies and non-invasive detection.Frontiers in oncology · 2024Review
- The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions.Stem cells translational medicine · 2023Article
- Small molecule-induced epigenomic reprogramming of APL blasts leading to antiviral-like response and c-MYC downregulation.Cancer gene therapy · 2023Article
- SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities.Molecular cancer · 2023Review
- SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.International journal of molecular sciences · 2022Review
- DDX56 transcriptionally activates MIST1 to facilitate tumorigenesis of HCC through PTEN-AKT signaling.Theranostics · 2022Article
- Extramedullary Hematopoiesis of the Liver and Spleen.Journal of clinical medicine · 2021Review
- p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.JCI insight · 2021Article
- The Route of Early T Cell Development: Crosstalk between Epigenetic and Transcription Factors.Cells · 2021Review
- Heterochromatin and Polycomb as regulators of haematopoiesis.Biochemical Society transactions · 2021Review
- Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments.Cancers · 2021Review
- Expression and Gene Regulation Network of Adenosine Receptor A2B in Lung Adenocarcinoma: A Potential Diagnostic and Prognostic Biomarker.Frontiers in molecular biosciences · 2021Article
- Article
- Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies.Human molecular genetics · 2020Review
- Bioinformatics analysis of the network of histone H3 lysine 9 trimethylation in acute myeloid leukaemia.Oncology reports · 2020Article
- Aberrant methylation of secreted protein acidic and rich in cysteine gene and its significance in gastric cancer.World journal of gastroenterology · 2019Article
- Review
- Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.Cell proliferation · 2019Article
- Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.Scientific reports · 2019Article
- Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic regulation in hematopoiesis has been a field of rapid expansion. Genome-wide analyses have revealed, and will continue to identify genetic alterations in epigenetic genes that are present in various types of hematopoietic neoplasms. Development of new mouse models for individual epigenetic modifiers has revealed their novel, sometimes unexpected, functions. In this review, we provide an overview of genetic alterations within epigenetic genes in various types of hematopoietic neoplasms. We then summarize the physiologic roles of these epigenetic modifiers during hematopoiesis, and describe therapeutic approaches targeting the epigenetic modifications. Interestingly, the mutational spectrum of epigenetic genes indicates that myeloid neoplasms are similar to T-cell neoplasms, whereas B-cell lymphomas have distinct features. Furthermore, it appears that the epigenetic mutations related to active transcription are more associated with myeloid/T-cell neoplasms, whereas those that repress transcription are associated with B-cell lymphomas. These observations may imply that the global low-level or high-level transcriptional activity underlies the development of myeloid/T-cell tumors or B-cell tumors, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.